

Basic Information

Product Name	Anti-BCL10 Antibody (Clone#GDB-2)	
Gene Name	BCL10	
Source	Rabbit	
Clonality	Monoclonal	
Isotype	IgG	
Species Reactivity	human	
Tested Application	WB, IHC, ICC/IF, IP	
Contents	500 ug/ml; Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide, 0.4-0.5 mg/ml BSA and 50% glycerol.	
Immunogen	A synthesized peptide derived from human Bcl10	
Concentration	500 ug/ml	
Purification	Affinity-chromatography	
Observed MW	26 kDa	
Dilution Ratios	Western blot (WB):	1:500-2000
	Immunohistochemistry (IHC):	1:50-200
	Immunocytochemistry/Immunofluorescence (ICC/IF):	1:50-200
	ImmunoPrecipitation (IP):	1:20


Storage

12 months from date of receipt, -20°C as supplied.


Background Information

BCL10, B-cell CLL/lymphoma 10, gene was identified by its translocation in a case of mucosa-associated lymphoid tissue(MALT) lymphoma. The BCL10 gene is mapped to chromosome 1p22. The protein encoded by this gene contains a caspase recruitment domain(CARD), and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are thought to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy.

Selected Validation Data



Western blot analysis of Bcl10 expression in (1) HeLa cell lysate; (2) Raji cell lysate.



Immunohistochemical analysis of paraffin-embedded human breast cancer, using Bcl10 Antibody.